HIGHLIGHT
Semglee

Semglee Use In Pregnancy & Lactation

insulin glargine

Manufacturer:

Biocon

Distributor:

DKSH

Marketer:

Viatris
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity.
The use of Semglee may be considered during pregnancy, if clinically needed.
It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential.
Breast-feeding: It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breast-fed newborn/infant are anticipated since insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract. Breast-feeding women may require adjustments in insulin dose and diet.
Fertility: Animal studies do not indicate direct harmful effects with respect to fertility.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in